Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis

Lourda, Magda; Olsson‐Åkefeldt, Selma; Gavhed, Désirée; Nygell, Ulla Axdorph; Berlin, Gösta; Laurenčikas, Evaldas; Greenwood, Tatiana von Bahr; Svensson, Mattias; Henter, Jan‐Inge

doi:10.1182/blood-2016-03-708107

Cited by 12 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to this finding, Colombatti and colleagues observed a significant reduction in AST post-HU therapy [22], which may be due to differences in the clinical profiles of individuals in the respective study groups. Based on their findings, Ragg and colleagues suggested that, in addition to increased HbF observed in individuals with SCD treated by HU, some clinical improvements may be the result of a reduced imbalance in serum protein levels [33].…”

Section: Discussionmentioning

confidence: 99%

Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia

et al. 2019

View full text Add to dashboard Cite

This study investigated the effects of hydroxyurea (HU) on hematological, biochemical and inflammatory parameters in children with sickle cell anemia (SCA) in association with β S haplotype and α-thalassemia. We included 22 children with SCA who were followed for an average of 14.5 months. Laboratory parameters were assessed by electronic methods, and molecular analysis was investigated by PCR-RFLP and allele-specific PCR. Results showed significant increases in hemoglobin, HbF, hematocrit, MCV, MCH, glucose, HDL-C and albumin levels, as well as significant decreases in MCHC and AST levels, WBC, neutrophils, eosinophils, lymphocytes and reticulocytes, in children during HU therapy. HbF levels were positively correlated with hemoglobin, hematocrit, MCV and total protein, yet negatively correlated with MCHC, RDW, AAT and AST during HU therapy ( p <0.05). Children who carried the Central African Republic haplotype, in response to HU therapy, presented significant increases in hemoglobin, hematocrit, triglycerides and uric acid levels, as well as significant decreases in MCHC, AST and direct bilirubin levels, WBC, neutrophils, eosinophils, lymphocytes and reticulocytes. Those with the Benin haplotype presented increases in HbF and albumin levels, and a reduction in platelet counts ( p <0.05). Children with α-thalassemia presented decreased ALT during HU use, while those without this deletion presented increases in hemoglobin, hematocrit, MCV, MCH, HDL-C and albumin, as well as decreases in MCHC, neutrophils, lymphocytes, reticulocytes and AST ( p <0.05). Hence, regardless of its use in association with β S haplotypes or α-thalassemia, HU seems to be linked to alterations in hemolytic, inflammatory, hepatic, lipid and glycemic profiles.

show abstract

Section: Discussionmentioning

confidence: 99%

Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For real‐time polymerase chain reaction, ribonucleic acid was extracted from snap‐frozen intestinal biopsies of patients undergoing colonoscopy, and the cytokines IL‐23, IL‐22 and IL‐17A were analysed as previously described 11 . IL‐23 in plasma was detected using enzyme‐linked immunosorbent assay, performed using an IL‐23 DuoSet ELISA kit (R&D Systems) as previously described 12 and LEGENDplex (BioLegend). Briefly, the plasma concentrations of IL‐23 and IL‐12p40 in patients with active LCH were measured using the LEGENDplex as per manufacturer's instructions, and LEGENDplex Data Analysis software (BioLegend) was used to determine the concentration of cytokines by comparing them against a set of standard curves.…”

Section: Methodsmentioning

confidence: 99%

Patients with both Langerhans cell histiocytosis and Crohn’s disease highlight a common role of interleukin‐23

et al. 2020

Self Cite

View full text Add to dashboard Cite

Aim To present the first case series of patients with Langerhans cell histiocytosis (LCH) also affected by Crohn's disease (CD), both of which are granulomatous diseases, and in LCH investigate the role of interleukin (IL)‐23, which is a well‐described disease mediator in CD. Methods A case series of three patients with LCH and CD were described; a cohort of LCH patients (n = 55) as well as controls (n = 55) were analysed for circulating IL‐23 levels; and the relation between the percentage of LCH cells in lesions and circulating IL‐23 levels was analysed in seven LCH patients. Results Differential diagnostic challenges for these two granulomatous diseases were highlighted in the case series, and it took up to 3 years to diagnose CD. Elevated IL‐23 levels were found in LCH patients. The amount of lesional LCH cells correlated with the levels of circulating IL‐23. Conclusion Both CD and LCH should be considered in patients with inflammatory gastrointestinal involvement. The IL‐23 pathway is a common immunological trait between these two granulomatous diseases.

show abstract

“…The highest level of IL-17A detected in the plasma of patients with LCH compared to healthy controls suggested that IL-17A may be involved in some pathogenic mechanisms of LCH. In agreement with this hypothesis, a longitudinal study of a patient with progressive neurodegenerative LCH documented that high IL-17A levels in both blood and cerebrospinal fluid evolve with the disease progression [7] . These findings will be of interest to clinicians and researchers to further test IL-17A as a potential biomarker in samples of LCH patients by both E_500-P07G and E_eBio64CAP17 ELISAs, as we have previously suggested [10] .…”

Section: Discussionmentioning

confidence: 55%

“…In Langerhans Cell Histiocytosis (LCH), a rare granulomatous disease, the detection of IL-17A in plasma of patients is still a matter of debate. A higher level of plasma IL-17A in LCH patients compared to healthy controls was reported by four laboratories, while another failed to demonstrate it or only to a very low level [4] , [5] , [6] , [7] , [8] , [9] , [10] . The origin of this apparent discrepancy is the use of different anti-IL-17A antibodies (Abs).…”

Section: Methods Detailsmentioning

confidence: 92%

Comparison of three different ELISAs for the detection of recombinant, native and plasma IL-17A

et al. 2020

Self Cite

View full text Add to dashboard Cite

Plasma IL-17A detection in Langerhans Cell Histiocytosis (LCH) is currently a source of debate. Indeed, 500-P07G (PeproTech) and 41802 (R&D Systems) anti-IL-17A antibodies have been suspected to recognize nonspecific proteins. To resolve this discrepancy, we set up two new ELISAs by using 41802 or neutralizing eBio64CAP17 (eBioscience) capture monoclonal antibodies that we compared to the commercial PeproTech ELISA kit. The three ELISAs, called E_500-P07G, E_41802 and E_eBio64CAP17, differ in their anti-IL-17A capture antibodies: either polyclonal, monoclonal or neutralizing monoclonal antibodies, respectively. Here, we show that these ELISAs had a similar capacity to specifically detect recombinant or native human IL-17A. However, a significantly lower plasma IL-17A detection was obtained with E_41802 compared to the two other ELISAs. Both E_500-P07G and E_eBio64CAP17 showed similar results. Consequently, we propose that the use of E_500-P07G and E_eBio64CAP17 may ensure more accurate and reliable results in the context of LCH studies. The highest plasma IL-17A levels in LCH patients compared to controls detected by both E_500-P07G and E_eBio64CAP17 ELISAs led us to propose these latter as reference techniques to investigate IL-17A as a potential new biomarker in LCH. The customization of a new E_eBio64CAP17 ELISA is suitable to detect human IL-17A. E_eBio64CAP17 ELISA protocol differs only in the anti-IL-17A capture antibody compared to the commercial E_500-P07G PeproTech kit. Data generated using the E_eBio64CAP17 ELISA are consistent with the PeproTech kit.

show abstract

Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis

Cited by 12 publications

References 17 publications

Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia

Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia

Patients with both Langerhans cell histiocytosis and Crohn’s disease highlight a common role of interleukin‐23

Comparison of three different ELISAs for the detection of recombinant, native and plasma IL-17A

Contact Info

Product

Resources

About